light. Transfusion 1997; 37(4):423–435.138 138. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35(1):5–17.
139 139. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium‐radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S‐59) and ultraviolet A light. Transfusion 2004; 44(12):1732–1740.
140 140. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46(5):731–740.
141 141. van Rhenen D. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101(6):2426–2433.
142 142. McCullough J. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104(5):1534–1541.
143 143. McCullough J. Pathogen inactivation: the penultimate paradigm shift. In: AuBuchon JP, Prowse CV, eds. Pathogen Inactivation: The Penultimate Paradigm Shift. Bethesda, MD: AABB Press, 2010, pp. 99–123.
144 144. Cazenave J‐P, Waller C, Kientz D, et al. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50(6):1210–1219.
145 145. Cazenave J‐P, Folléa G, Bardiaux L, et al. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50(11):2362–2375.
146 146. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen‐UVA photochemical treatment. Vox Sang 2015; 109(4):343–352.
147 147. Cancelas J, Rugg N, Pratt P, et al. In vivo performance and correlation with in vitro parameters of stored RBCs obtained from whole blood treated with mirasol. Transfusion 2010; 50:10A (abstract).
148 148. Cancelas J, Rugg N, Dumont L. Comprehensive evaluation of a new process for S‐303 pathogen‐inactivation of red blood cells. Transfusion 2010; 50:9A (abstract).
149 149. Wages D, Hambleton J, Viele M. RBCs treated with Helinx pathogen inactivation show comparable recovery and survival to standard RBCs in a randomized crossover trial. Blood 2001; 8:449a (abstract).
150 150. Rios J, Hambleton J, Viele M. Helinx treated RBC transfusions are well tolerated and show comparable recovery and survival to control RBCs. Transfusion 2001; 41:S135 (abstract).
151 151. Winter KM, Johnson L, Kwok M, et al. Red blood cell in vitro quality and function is maintained after S‐303 pathogen inactivation treatment. Transfusion 2014; 54(7):1798–1807.
152 152. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S‐303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45(11):1739–1749.
153 153. Aydinok Y, Piga A, Origa R, et al. Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemia. Br J Haematol 2019; 186(4):625–636.
154 154. Aydinok Y, Piga A, Origa R, et al. Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemia. Br J Haematol 2019; 186(4):625–636.
155 155. Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light‐treated whole blood. Transfusion 2011; 51(7):1460–1468.
156 156. Allain J‐P, Owusu‐Ofori A, Assennato SM, et al. Prevention of transfusion‐transmitted malaria by treatment of whole blood with the mirasol PRT system. Blood 2015; 126:770 (abstract).
157 157. Kruskall MS, AuBuchon JP, Anthony KY, et al. Transfusion to blood group A and O patients of group B RBCs that have been enzymatically converted to group O. Transfusion 2000; 40(11):1290–1298.
158 158. Olsson ML, Clausen H. Modifying the red cell surface: towards an ABO‐universal blood supply. Br J Haematol 2008; 140(1):3–12.
159 159. Bradley AJ, Test ST, Murad KL, et al. Interactions of IgM ABO antibodies and complement with methoxy‐PEG‐modified human RBCs. Transfusion 2001; 41(10):1225–1233.
160 160. Silverman T, Weiskopf R. Hemoglobin‐based oxygen carriers: current status and future directions. Transfusion 2009; 49:2495–2515.
161 161. Stowell CP, Levin J, Spiess BD, Winslow RM. Progress in the development of RBC substitutes. Transfusion 2001; 41(2):287–299.
162 162. Bachert SE, Dogra P, Boral LI. Alternatives to transfusion. Am J Clin Pathol 2020; 153(3):287–293.
163 163. Brotman I, Kocher M, McHugh S. Bovine hemoglobin‐based oxygen carrier treatment in a severely anemic Jehovah’s witness patient after cystoprostatectomy and nephrectomy. A A Pract 2019; 12(7):243–245.
164 164. Sloan EP. Diaspirin cross‐linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock. A randomized controlled efficacy trial. JAMA 1999; 282(19):1857.
165 165. Winslow R. αα‐crosslinked hemoglobin: was failure predicted by preclinical testing? Vox Sang 2000; 70:1–20.
166 166. Mullon J, Giacoppe G, Clagett C, et al. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med 2000; 342(22):1638–1643.
167 167. Lanzkron S, Moliterno AR, Norris EJ, et al. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion 2002; 42(11):1422–1427.
168 168. Moore EE, Moore FA, Fabian TC, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg 2009; 208(1):1–13.
169 169. Winslow RM. Red cell substitutes. Semin Hematol 2007; 44(1):51–59.
170 170. Davis JM, El‐Haj N, Shah NN, et al. Use of the blood substitute HBOC‐201 in critically ill patients during sickle crisis: a three‐case series. Transfusion 2018; 58(1):132–137.
171 171. Expanded Access Study of HBOC‐201 (Hemopure) for the Treatment of Life‐Threatening Anemia. NCT01881503. Available from: https://clinicaltrials.gov/ct2/show/NCT01881503 (cited November 6, 2019).
172 172. Gould SA, Rosen AL, Sehgal LR, et al. Fluosol‐DA as a Red‐Cell Substitute in Acute Anemia. N Engl J Med 1986; 314(26):1653–1656.
6 Production of Components by Apheresis
Thomas Gniadek MD, PhD
Although collected whole blood can be separated into its component parts (e.g., plasma, platelets, and packed red blood cells [RBCs]), the amount of each component collected from a single donor is limited in this approach by the amount of whole blood that can be collected at one time. As the demand for blood components
